Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/126545
Title: | Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models |
Author: | Daldin, Manuel Fodale, Valentina Cariulo, Cristina Azzollini, Lucia Verani, Margherita Martufi, Paola Spiezia, Maria Carolina Deguire, Sean M. Cherubini, Marta Macdonald, Douglas Weiss, Andreas Bresciani, Alberto Vonsattel, Jean-Paul Gerard Petricca, Lara Marsh, J. Lawrence Ginés Padrós, Silvia Santimone, Iolanda Marano, Massimo Lashuel, Hilal A. Squitieri, Ferdinando Caricasole, Andrea |
Keywords: | Corea de Huntington Malalties neurodegeneratives Mutació (Biologia) Huntington's chorea Neurodegenerative Diseases Mutation (Biology) |
Issue Date: | 11-Jul-2017 |
Publisher: | Nature Publishing Group |
Abstract: | Conformational changes in disease-associated or mutant proteins represent a key pathological aspect of Huntington's disease (HD) and other protein misfolding diseases. Using immunoassays and biophysical approaches, we and others have recently reported that polyglutamine expansion in purified or recombinantly expressed huntingtin (HTT) proteins affects their conformational properties in a manner dependent on both polyglutamine repeat length and temperature but independent of HTT protein fragment length. These findings are consistent with the HD mutation affecting structural aspects of the amino-terminal region of the protein, and support the concept that modulating mutant HTT conformation might provide novel therapeutic and diagnostic opportunities. We now report that the same conformational TR-FRET based immunoassay detects polyglutamine-and temperaturedependent changes on the endogenously expressed HTT protein in peripheral tissues and post-mortem HD brain tissue, as well as in tissues from HD animal models. We also find that these temperatureand polyglutamine-dependent conformational changes are sensitive to bona-fide phosphorylation on S13 and S16 within the N17 domain of HTT. These findings provide key clinical and preclinical relevance to the conformational immunoassay, and provide supportive evidence for its application in the development of therapeutics aimed at correcting the conformation of polyglutamine-expanded proteins as well as the pharmacodynamics readouts to monitor their efficacy in preclinical models and in HD patients. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41598-017-05336-7 |
It is part of: | Scientific Reports, 2017, vol. 7 |
URI: | http://hdl.handle.net/2445/126545 |
Related resource: | https://doi.org/10.1038/s41598-017-05336-7 |
ISSN: | 2045-2322 |
Appears in Collections: | Articles publicats en revistes (Biomedicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
675692.pdf | 2.76 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License